Generated by AI
Palatin Technologies Inc. is a biopharmaceutical company focused on developing first-in-class medicines that act on the melanocortin receptor system. Its current portfolio centers on receptor-targeted therapeutics for obesity, rare neuroendocrine disorders, inflammatory conditions, autoimmune diseases, and ocular disorders. The company’s work includes product candidates and partnered programs designed to address areas with significant unmet medical need, with a focus on selective peptide and small-molecule approaches. Palatin Technologies also participates in collaboration and licensing activities that support its research and development efforts across multiple therapeutic areas. Based in Princeton, New Jersey, Palatin Technologies Inc. operates as a clinical-stage company within the healthcare sector, where it contributes to the development of novel treatments aimed at specialized patient populations.
Website301 Carnegie Center Drive
Princeton, NJ, 08540
United States
The latest articles about PTN.
Palatin Technologies, Inc. (Nasdaq: PTN) will announce its first quarter fiscal year 2027 operating results on Tuesday, November 17, 2026, before the open of the U.S. financial markets.
Summary of Apr 19's posts. Generated by AI.
Summary of Nov 21's posts. Generated by AI.
Summary of Nov 24's posts. Generated by AI.
Summary of Dec 20's posts. Generated by AI.
Investors talking about PTN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.